首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >Autoradiographic reevaluation of the binding properties of 125I-(Leu31,Pro34)peptide YY and 125I-peptide YY3-36 to neuropeptide Y receptor subtypes in rat forebrain.
【24h】

Autoradiographic reevaluation of the binding properties of 125I-(Leu31,Pro34)peptide YY and 125I-peptide YY3-36 to neuropeptide Y receptor subtypes in rat forebrain.

机译:放射自显影重新评估大鼠前脑中125I-(Leu31,Pro34)肽YY和125I-肽YY3-36与神经肽Y受体亚型的结合特性。

获取原文
获取原文并翻译 | 示例
           

摘要

125I-[Leu31,Pro34]peptide YY (PYY) and 125I-PYY3-36, initially described as selective neuropeptide Y Y1 and Y2 receptor ligands, respectively, were recently shown to label also Y4 and Y5 receptors. We used receptor autoradiography to assess whether these ligands can be reliably used to investigate the various neuropeptide Y receptors in rat forebrain. In most of the brain regions examined (in coronal sections at the level of dorsal hippocampus), specific 125I-[Leu31,Pro34]PYY binding was completely inhibited by 1 microM BIBP-3226, a selective Y1 receptor ligand, but unaffected by 10 nM rat pancreatic polypeptide, selectively inhibiting Y4 receptors, suggesting that Y4 receptors are present in negligible numbers compared with Y1 receptors in the areas examined. Significant numbers of BIBP-3226-insensitive 125I-[Leu31,Pro34]PYY binding sites were measured in the CA3 subfield of the hippocampus only, possibly representing Y5 receptors. 125I-PYY3-36 binding was unchanged by 1 microM BIBP-3226, whereas a population of 125I-PYY3-36 binding sites was sensitive to 100 nM [Leu31,Pro34]neuropeptide Y, likely representing Y5 receptors. The possibility of distinguishing between Y2 and Y5 receptors using 125I-PYY3-36 as radioligand was validated by their different regional distribution and their distinct changes 24 h after kainate seizures, i.e., binding to Y5 receptors was selectively decreased in the outer cortex, whereas binding to Y2 receptors was enhanced in the hippocampus. Thus, the use of selective unlabeled compounds is required for distinguishing the various receptor subtypes labeled by 125I-[Leu31,Pro34]PYY and 125I-PYY3-36 in rat brain tissue.
机译:最初分别被描述为选择性神经肽Y Y1和Y2受体配体的125I- [Leu31,Pro34] YY肽(PYY)和125I-PYY3-36最近被证明也标记Y4和Y5受体。我们使用受体放射自显影来评估这些配体是否可以可靠地用于研究大鼠前脑中的各种神经肽Y受体。在检查的大多数大脑区域(在海马背侧的冠状切片中),特异性125 I- [Leu31,Pro34] PYY结合都被1 microM BIBP-3226(一种选择性的Y1受体配体)完全抑制,但不受10 nM影响大鼠胰腺多肽,选择性抑制Y4受体,提示在所检查区域中,Y4受体的数量与Y1受体相比可忽略不计。仅在海马的CA3子域中测量了BIBP-3226不敏感的125I- [Leu31,Pro34] PYY结合位点的重要数量,可能代表Y5受体。 125 I-PYY3-36的结合在1 microM BIBP-3226中没有改变,而125I-PYY3-36的结合位点对100 nM [Leu31,Pro34]神经肽Y敏感,可能代表Y5受体。通过125I-PYY3-36作为放射性配体区分Y2和Y5受体的可能性通过其不同的区域分布和在海藻酸盐发作后24 h发生明显变化来验证,即与Y5受体的结合在外皮层选择性降低,而结合Y2受体在海马中增强。因此,需要使用选择性的未标记化合物来区分大鼠脑组织中125I- [Leu31,Pro34] PYY和125I-PYY3-36标记的各种受体亚型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号